Genetic testing for patients at risk of hereditary breast and ovarian cancer
Alisha DeTroye1, Kayla Gabbett, Cheryl Yi
1Alisha DeTroye is regional director of advanced practice at Atrium Health Wake Forest Baptist, practices in hematology and oncology and is an adjunct assistant professor in the PA program at Wake Forest School of Medicine in Winston-Salem, N.C. Kayla Gabbett practices at Chester County Hospital in West Chester, Pa., Cheryl Yi practices at Newport Orthopedic Institute in Newport Beach, Calif. Melanie Judice practices at Texas Spine and Scoliosis in Austin, Tex. Victor Luu practices at Brigham and Women's Hospital in Boston, Mass. Brittany Nelson practices at the Sansum Clinic Internal Medicine in Santa Barbara, Calif. Tanya Gregory is an assistant professor and director of the Office of Academic Excellence in the PA program at Wake Forest School of Medicine. The authors have disclosed no potential conflicts of interest, financial or otherwise.
Abstract:
The field of cancer genetic testing has made great advances in correctly identifying patients at risk for hereditary cancer syndromes. These tests, used during a genetic consultation, promote earlier detection of cancer and potentially increase survival. Despite these advancements, a large number of persons at risk for BRCA1/2 mutations remain untested due to a shortage of genetic counselors and lack of clinician knowledge on how to properly screen, identify, and refer patients to genetic counseling. We suggest team-based practices that physician associates/assistants (PAs) and NPs can use in collaboration with genetic counselors. We also explore how PAs and NPs can alleviate the burden on genetic counselors by taking a comprehensive family history, providing elements of counseling, and ordering appropriate genetic tests. This approach maximizes the amount of time the patient spends receiving actual genetic counseling. By creating this collaborative relationship, PAs and NPs can help increase the number of qualifying patients who receive genetic testing and counseling for hereditary breast and ovarian cancer syndromes.
More Related Videos
13:04In Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose
Published on: October 14, 2015
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Related Concept Videos
Cancer Prevention
Some...
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
